Arvinas Inc Revenue Growth Rates (ARVN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Arvinas Inc   (NASDAQ: ARVN)
 

ARVN's Revenue Growth by Quarter and Year

Arvinas Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ARVN Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 249.70
1st Quarter March 15.60
FY 265.30

ARVNs Annual Revenue
Arvinas Inc 's Revenue in the fiscal year 2025 $ 262.60 millions
Arvinas Inc 's Revenue in the fiscal year 2024 $ 263.40 millions
Arvinas Inc 's Revenue in the fiscal year 2023 $ 78.50 millions
Arvinas Inc 's Revenue in the fiscal year 2022 $ 131.40 millions
Arvinas Inc 's Revenue in the fiscal year 2021 $ 46.70 millions




ARVN Revenue second quarter 2026 Y/Y Growth Comment
Arvinas Inc achieved in the second quarter 2026, above Company average Revenue surge of 1014.73% year on year, to $ 249.70 millions.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 136 other companies have achieved higher Revenue growth. While Arvinas Inc ' s Revenue doubling of 1014.73% ranks overall at the positon no. 3097 in the second quarter 2026.


ARVN Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -83.95 % - -
3rd Quarter September - -59.08 % 195.95 % 4.22 %
2nd Quarter June 1014.73 % -70.72 % 40.37 % 61.24 %
1st Quarter March -91.74 % 646.25 % -22.15 % 22.64 %
FY   - -0.3 % 235.54 % -

Financial Statements
Arvinas Inc 's second quarter 2026 Revenue $ 249.70 millions ARVN's Income Statement
Arvinas Inc 's second quarter 2025 Revenue $ 22.40 millions Quarterly ARVN's Income Statement


ARVN Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -77.33 % -42.19 % -
3rd Quarter September - 87.05 % 33.86 % -36.51 %
2nd Quarter June 1500.64 % -88.14 % 202.37 % 67.69 %
1st Quarter March 64.21 % 218.92 % - -28.73 %
FY (Year on Year)   - -0.3 % 235.54 % -


Back to ARVN Growth rate Comparisons >> Back to ARVN Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #137
Healthcare Sector #422
Overall #3097

Revenue Y/Y Growth Statistics
High Average Low
497.9 % 102.95 % -79.06 %
(Mar 31 2025)   (Mar 31 2026)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #137
Healthcare Sector #422
Overall #3097
Revenue Y/Y Growth Statistics
High Average Low
497.9 % 102.95 % -79.06 %
(Mar 31 2025)   (Mar 31 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Arvinas Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1500.64 % 83.52 % -88.14 %
(Jun 30 2026)  


ARVN's II. Quarter Q/Q Revenue Comment
Arvinas Inc achieved in the II. Quarter 2026 above company average sequential Revenue doubling of 1500.64%, to $ 249.70 millions, from $15.60 millions in the first quarter.
ARVN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 5 other companies have achieved higher Revenue quarter on quarter growth. While Arvinas Inc 's Revenue growth quarter on quarter, overall rank is 18.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #6
Healthcare Sector #8
Overall #18
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #6
Healthcare Sector #8
Overall #18
Revenue Q/Q Growth Statistics
High Average Low
1500.64 % 83.52 % -88.14 %
(Jun 30 2026)  


ARVN's II. Quarter Q/Q Revenue Comment
Arvinas Inc achieved in the II. Quarter 2026 above company average sequential Revenue doubling of 1500.64%, to $ 249.70 millions, from $15.60 millions in the first quarter.
ARVN is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 5 other companies have achieved higher Revenue quarter on quarter growth. While Arvinas Inc 's Revenue growth quarter on quarter, overall rank is 18.


Arvinas Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 316.70 $ 89.40 $ 262.60 $ 312.30 $ 372.80
Y / Y Revenue Growth (TTM) -15.05 % -79.06 % -0.3 % 93.85 % 299.57 %
Year on Year Revenue Growth Overall Ranking # 60 # 65 # 0 # 2254 # 3414
Seqeuential Revenue Change (TTM) 254.25 % -65.96 % -15.91 % -16.23 % -12.67 %
Seq. Revenue Growth (TTM) Overall Ranking # 3097 # 237 # 0 # 238 # 2873


Cumulative Revenue growth Comment
Arvinas Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Arvinas Inc 's annual Revenue fall would be -15.05% year on year to $317 millions.

Among companies within the Healthcare sector 20 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 60, from total ranking in previous quarter at 65.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 137
Healthcare Sector # 21
Overall # 60

Revenue TTM Y/Y Growth Statistics
High Average Low
497.9 %
 102.95 %
-79.06 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 137
Sector # 422
S&P 500 # 3097
Cumulative Revenue growth Comment
Arvinas Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2026. If the fiscal year would end in Jun 30 2026, Arvinas Inc 's annual Revenue drop would be -15.05% year on year to $317 millions.

Among companies within the Healthcare sector 20 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 60, from total ranking in previous quarter at 65.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 137
Healthcare Sector # 21
Overall # 60

Revenue TTM Y/Y Growth Statistics
High Average Low
497.9 %
102.95 %
-79.06 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 137
Sector # 422
S&P 500 # 3097




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ARVN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Verastem Inc 1,775.43%$ 1,775.433 millions
EBR Systems, Inc.1,453.92%$ 1,453.919 millions
Safe Pro Group Inc 1,336.15%$ 1,336.152 millions
Capforce Inc 1,150.00%$ 1,150.000 millions
Crispr Therapeutics Ag1,041.37%$ 1,041.368 millions
Arvinas Inc 1,014.73%$ 1,014.732 millions
Abeona Therapeutics Inc 697.48%$ 697.477 millions
Nuvation Bio Inc 644.35%$ 644.350 millions
Tonix Pharmaceuticals Holding Corp 577.88%$ 577.878 millions
Allogene Therapeutics Inc 567.50%$ 567.500 millions
Brightspring Health Services Inc 555.52%$ 555.518 millions
Bullfrog Ai Holdings Inc 547.64%$ 547.638 millions
Northwest Biotherapeutics Inc516.03%$ 516.031 millions


About Arvinas Inc Revenue Growth Rates (ARVN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Arvinas Inc (CIK 1655759).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-26-052554
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Arvinas Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.